BioCentury on BioBusiness,
Guest Commentary: Why it's time to modify SEC disclosure rules for biotech
Guest Commentary: Reducing the burden of disclosure
Monday, April 14, 2014
Much has been written about
rocketing biotech stocks and the opening of public markets to biotech companies
over the past 18 months. But access to public funding brings with it
substantial costs and regulatory burdens imposed by the disclosure requirements
of U.S. securities laws. Public companies undertake an onerous burden of
providing disclosure, sometimes with so much detail that investors are
It is therefore timely that the chair of the Securities
and Exchange Commission, Mary Jo White, is acknowledging this
disclosure burden and mandating that SEC staff undertake regulatory changes to
reduce it. This presents an opportunity for biotech companies and BIO to make
their voices heard and provide recommendations to the SEC on what changes would
reduce the disclosure burden while still providing investors with the
information necessary to make investment decisions.
words displayed of
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2016 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement
. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions
. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial Subscription 4 Weeks of Access
BioCentury's Weekly Business Intelligence Journal
Get a 4-week free trial subscription to BioCentury.
Get 4 Weeks Free
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
close [ X ]